Assertio and Garda Extend Tender Offer Deadline to May 4

*TL;DR: Assertio Holdings (NASDAQ: ARTX) and Garda Therapeutics (NASDAQ: GARD) have agreed to move the tender‑offer deadline to May 4, and the offer has not yet begun.

Context On April 8, 2026, Assertio entered a definitive agreement to be acquired by Garda. The deal will be executed through Garda’s wholly‑owned subsidiary, Audi Merger Sub, Inc. A tender offer—an invitation to shareholders to sell their shares at a set price—will be filed with the SEC before it can be launched.

Key Facts - The parties mutually consented to extend the deadline for shareholders to tender shares to May 4, 2026. - No tender offer has been filed; investors must wait for the Schedule TO filing that will contain the purchase price, breakup fee (a penalty if the deal falls apart), and any contingent value rights (additional compensation tied to future performance). - Assertio’s stock traded at $7.12, up 2.3% on the news, giving the company a market capitalization of roughly $1.1 billion. Garda shares rose 1.8% to $22.45, reflecting market confidence in the pending merger. - The extension aligns the timeline with regulatory filing requirements and gives shareholders more time to review the forthcoming Schedule 14D‑9 solicitation/recommendation statement, which will detail the offer’s terms.

What It Means The deadline shift does not alter the agreed purchase price but postpones the window in which shareholders can decide to sell. Until the tender offer is formally announced, the transaction remains contingent on satisfying closing conditions, such as regulatory approvals and the absence of a material adverse change in either company’s business. Investors should monitor the SEC’s EDGAR system for the Schedule TO filing and the Schedule 14D‑9 statement, which will become publicly available at no cost.

Looking Ahead Watch for the official tender‑offer filing in the coming weeks and any updates on regulatory clearance that could affect the May 4 deadline.